Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel formulation of QRL-101 safety study in healthy participants
NL-OMON59655Phase 1Completed
- Sponsor
- QurAlis
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of QRL-101 in epilepsy, amyotrophic lateral sclerosis (ALS) and neuropathy, sponsored by QurAlis. Primary endpoint: Primary endpoint(s). Started Feb 2026; status: completed.
02
Drugs
QRL-101
03
Conditions
epilepsyamyotrophic lateral sclerosis (ALS)neuropathy
Beyond the preview
Go deeper on NL-OMON59655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59655.